venBio Select Advisor LLC raised its holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 35.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,275,000 shares of the biotechnology company’s stock after buying an additional 331,500 shares during the period. Sarepta Therapeutics makes up approximately 8.3% of venBio Select Advisor LLC’s portfolio, making the stock its 3rd largest position. venBio Select Advisor LLC owned 1.91% of Sarepta Therapeutics worth $139,141,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Cornerstone Advisors Inc. acquired a new stake in Sarepta Therapeutics during the 3rd quarter worth $25,000. Oppenheimer Asset Management Inc. acquired a new stake in Sarepta Therapeutics during the 4th quarter worth $51,000. Larson Financial Group LLC acquired a new stake in Sarepta Therapeutics during the 4th quarter worth $55,000. Ffcm LLC raised its stake in Sarepta Therapeutics by 31.1% during the 4th quarter. Ffcm LLC now owns 1,311 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 311 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in Sarepta Therapeutics by 168.3% during the 4th quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 1,610 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 1,010 shares in the last quarter.
Several equities research analysts recently commented on SRPT shares. HC Wainwright set a $267.00 price target on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 10th. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Royal Bank of Canada reiterated an “outperform” rating and set a $164.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, January 17th. BMO Capital Markets started coverage on shares of Sarepta Therapeutics in a research note on Tuesday. They set an “outperform” rating on the stock. Finally, Morgan Stanley lifted their price target on shares of Sarepta Therapeutics from $161.00 to $169.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Four equities research analysts have rated the stock with a hold rating, twenty-five have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $189.86.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, February 27th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.08) by $0.23. The business had revenue of $84.40 million for the quarter, compared to the consensus estimate of $84.83 million. Sarepta Therapeutics had a negative net margin of 120.22% and a negative return on equity of 36.73%. The business’s quarterly revenue was up 47.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. On average, research analysts forecast that Sarepta Therapeutics Inc will post -5.17 EPS for the current year.
In other news, SVP David T. Howton sold 30,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $140.00, for a total value of $4,200,000.00. Following the sale, the senior vice president now owns 31,196 shares of the company’s stock, valued at $4,367,440. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Sandesh Mahatme sold 65,000 shares of Sarepta Therapeutics stock in a transaction dated Thursday, February 7th. The shares were sold at an average price of $145.00, for a total transaction of $9,425,000.00. Following the completion of the sale, the chief financial officer now directly owns 73,649 shares in the company, valued at approximately $10,679,105. The disclosure for this sale can be found here. In the last ninety days, insiders sold 160,000 shares of company stock worth $22,089,950. Insiders own 7.90% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/4223963/venbio-select-advisor-llc-has-139-14-million-holdings-in-sarepta-therapeutics-inc-srpt.html.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Featured Story: How are the companies in the S&P 500 selected?
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.